|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Caspase-8 is frequently mutated or silenced in several tumors including hepatocellular carcinomas (HCC) thereby potentially contributing to chemoresistance.
|
17922191 |
2007 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the CASP8 -652 6N ins/del polymorphism may play a protective role in the development, progression, and survival of HBV-related HCC among the Chinese Han population.
|
28643196 |
2017 |
|
Liver carcinoma
|
0.900 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of the caspase 8 and survivin gene was analyzed in 73 primary HCC using methylation-specific polymerase chain reaction.
|
20403046 |
2010 |
|
Liver carcinoma
|
0.900 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of combining wild-type p53 gene transduction by adenoviral infection (Ad-p53) with addition of TRAIL on cell death, expression levels of TRAIL receptors (TRAIL-R1, TRAIL-R2), FLICE inhibitory protein (FLIP) and X-linked inhibitor of apoptosis protein (XIAP) on human hepatocellular carcinoma (HCC) cell lines.
|
15254777 |
2004 |
|
Liver carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
This study has investigated whether galangin, a flavonol derived from Alpinia officinarum Hance and used as food additives in southern China, induces apoptosis in hepatocellular carcinoma cells (HCCs) by activation of the caspase-8 and Bid pathway.
|
22575016 |
2012 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Also, the data suggest that caspase-8 gene mutation might lead to the loss of its cell death function and contribute to the pathogenesis of HCC.
|
15531912 |
2005 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Targeted stimulation of the caspase-8 promoter by interferons alpha and gamma, cytotoxic drugs or p53 can substantially sensitize hepatoma cells for apoptosis, whereas hepatocellular carcinoma frequently present an inactive caspase-8 gene promoter.
|
22153863 |
2012 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
|
19728331 |
2010 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A dose-dependent association was observed between the risk of breast cancer and the genetic risk score, which was an aggregate measure of alleles in seven selected variants, namely FGFR2-rs2981579, TOX3/TNRC9-rs3803662, C6orf97-rs2046210, 8q24-rs13281615, SLC4A7-rs4973768, LSP1-rs38137198, and CASP8-rs10931936.
|
22160591 |
2012 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
For Caucasians, CASP8-652 6N del was associated with reduced breast cancer risk at a borderline level (homozygous: OR=0.94, 95% CI 0.86-1.02, heterozygous: OR=0.96, 95% CI 0.90-1.03, recessive: OR=0.96, 95% CI 0.90-1.03, dominant: OR=0.94, 95% CI 0.88-1.01).
|
24457433 |
2014 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Five miRNA binding site SNPs associated significantly with breast cancer risk: rs1045494 (odds ratio (OR) 0.92; 95% confidence interval (CI): 0.88-0.96), rs1052532 (OR 0.97; 95% CI: 0.95-0.99), rs10719 (OR 0.97; 95% CI: 0.94-0.99), rs4687554 (OR 0.97; 95% CI: 0.95-0.99, and rs3134615 (OR 1.03; 95% CI: 1.01-1.05) located in the 3' UTR of CASP8, HDDC3, DROSHA, MUSTN1, and MYCL1, respectively.
|
25390939 |
2014 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.
|
17450141 |
2007 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study contributes to our understanding of CASP8 SNPs and breast cancer risk by subtype.
|
26758508 |
2016 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
The reproducible, dose-dependent association of CASP8 D302H with breast cancer indicates the potential importance of inherited variation in the apoptosis pathway in breast cancer susceptibility.
|
15601643 |
2004 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.
|
26426685 |
2015 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analyses, we observed a significantly decreased risk of breast cancer associated with the homozygous minor allele of CASP8 D302H [rs1045485, odds ratio (OR), 0.3; 95% confidence interval (95% CI), 0.1-0.8].
|
17932347 |
2007 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.
|
29915430 |
2018 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85-0.94) and 0.74 (95% c.i.
|
17293864 |
2007 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel.
|
25374178 |
2014 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.
|
19214744 |
2010 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We observed an allele-dose dependent association between CASP8 -652 6N InsDel and caspase 8 mRNA expression in breast cancer tissue, with homozygous deletion carriers showing lowest relative caspase 8 expression (p = 0.0131).
|
27507139 |
2016 |